CANTA — Cantargia AB Share News
0.000.00%
Last trade - 00:00- SEK399.02m
- SEK177.07m
- SEK316.70m
Brief: Cantargia Q1 Operating Loss Narrows To SEK 77.6 Mln
Brief: Cantargia Intensifies Development Of Nadunolimab In Pancreatic Cancer With Controlled Phase IIb Clinical Trial
Brief: Cantargia Presents Positive Results For Nadunolimab At Aacr 2023 Including New Clinical Data In Pancreatic Cancer
Brief: Cantargia Presents Positive Results For Nadunolimab At Aacr 2023
Brief: Cantargia FY Net Loss SEK 371.8 Million
Brief: Cantargia Appoints Patrik Renblad As CFO
Brief: Cantargia Successfully Concludes Toxicity Study With CAN10 Antibody
Brief: Cantargia Q3 Operating Loss SEK 74.2 Mln
Brief: Cantargia Says Can10 Shows Positive Activity In Systemic Sclerosis Models
Brief: Cantargia Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy
Brief: Cantargia Presents Preclinical Data Demonstrating Unique Treatment Effects Of Nadunolimab On Pancreatic Cancer Stromal Cells
Brief: Cantargia Presents Preclinical Data Demonstrating Unique Treatment Effects Of Nadunolimab On Pancreatic Cancer Stromal Cells
Brief: Cantargia Q2 Operating Loss At SEK 96.0 Million
Brief: Cantargia's Rights Issue Oversubscribed
Brief: Cantargia Reports New Positive Data For CAN10
Brief: Cantargia Receives USPTO Notice Of Allowance For Composition Of Matter Patent On Antibody CAN10
Brief: Cantargia: Terms Of Fully Covered Rights Issue Of SEK 250 Mln
Brief: Cantargia Appoints Dr. Dominique Tersago As Chief Medical Officer
Brief: Cantargia Resolves On A Fully Covered Rights Issue Of Approximately SEK 250 Million